Auscann Group Holdings Ltd
ASX:AC8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zhejiang Sanhua Intelligent Controls Co Ltd
SZSE:002050
|
CN |
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
CN |
Auscann Group Holdings Ltd
Cash from Operating Activities
Auscann Group Holdings Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Auscann Group Holdings Ltd
ASX:AC8
|
Cash from Operating Activities
-AU$2.3m
|
CAGR 3-Years
38%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-16%
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Cash from Operating Activities
-AU$2.6m
|
CAGR 3-Years
44%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash from Operating Activities
AU$17.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash from Operating Activities
AU$125.4m
|
CAGR 3-Years
227%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cash from Operating Activities
-AU$54.8m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Cash from Operating Activities
-AU$7.3m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
Auscann Group Holdings Ltd
Glance View
AusCann Group Holdings Ltd. engages in development, production, and distribution of cannabinoid-based medicines within Australia and internationally. The company is headquartered in Perth, Western Australia. The firm focuses on providing healthcare professionals and veterinarians with pharmaceutical and nutraceutical products to support the treatment of their patients. Its controlled-dose technology platform, Neuvis, is for delivering cannabinoids to human patients through CannPal Animal Therapeutics Pty Ltd. DermaCann is its lead cannabidiol (CBD) derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. CPAT-01 is a liquid, oral veterinary medicine containing tetrahydrocannabinol (THC) and CBD whole plant extracts in a combined ratio to cure pain and inflammation in dogs. CPAT-01 is in Phase II clinical trials. AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited are its subsidiaries.
See Also
What is Auscann Group Holdings Ltd's Cash from Operating Activities?
Cash from Operating Activities
-2.3m
AUD
Based on the financial report for Dec 31, 2023, Auscann Group Holdings Ltd's Cash from Operating Activities amounts to -2.3m AUD.
What is Auscann Group Holdings Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-16%
Over the last year, the Cash from Operating Activities growth was -20%. The average annual Cash from Operating Activities growth rates for Auscann Group Holdings Ltd have been 38% over the past three years , 17% over the past five years , and -16% over the past ten years .
